Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Menitorix or MenC and Pneumococcal Vaccines in Children
NCT00891176Phase 3
Key facts
- Status
- Completed
- Start
- May 2009
- Primary completion
- Nov 2012
- Countries
- 3
- Sponsor
- GSK
- Modality
- Split/Subunit Vaccines
- Conditions
- meningococcal meningitisHaemophilus influenzae type b infection (Hib)pneumococcal infectionhepatitis B (HBV)
01
Overview
Phase 3, open-label trial of Hib-MenC-TT and 10-valent pneumococcal conjugate vaccine in meningococcal meningitis, Haemophilus influenzae type b infection (Hib), pneumococcal infection and 1 more, sponsored by GSK. Started May 2009; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Registry description
This protocol posting deals with objectives \& outcome measures of an extension phase when subjects are aged 3, 4 and 6 years of age. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334). The objectives \& outcome measures of the booster phase are presented in a separate protocol posting (NCT number = NCT00463437).
The purpose of this study is to evaluate the persistence of pneumococcal, meningococcal serogroup C, Hib and Hepatits B antibodies after booster vaccination, when the subjects are aged 3, 4 and 6 years. No…
Beyond the preview
Go deeper on NCT00891176.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00891176.